X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.pharmatimes.com/news/nice_recommends_takedas_ninlaro_triplet_regimen_1485592
https://www.europeanpharmaceuticalreview.com/news/178699/nice-recommends-ixazomib-all-oral-treatment-for-multiple-myeloma/
https://www.globenewswire.com/news-release/2022/02/07/2379644/0/en/Active-Biotech-announces-first-patient-dosed-in-the-combination-part-of-the-phase-Ib-IIa-study-of-tasquinimod-in-multiple-myeloma.html
https://seekingalpha.com/news/3612814-takedas-ixazomib-comes-up-short-in-first-line-multiple-myeloma-study
https://www.takeda.com/newsroom/newsreleases/2020/takeda-presents-positive-data-from-clinical-trial-evaluating-oral-ninlaro-ixazomib--in-multiple-myeloma-as-a-first-line-maintenance-therapy/
http://www.pharmafile.com/news/543451/takedas-ninlaro-combo-fails-hit-main-goal-newly-diagnosed-transplant-ineligible-multiple
https://www.businesswire.com/news/home/20191107005221/en/Phase-3-Trial-NINLAROTM-ixazomib-Line-Maintenance/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.fiercepharma.com/pharma/takeda-scores-a-win-for-ninlaro-as-it-aims-to-pioneer-switch-maintenance-multiple-myeloma
https://endpts.com/ema-and-fda-historically-agree-on-just-about-every-new-drug-approval-but-is-that-slowly-changing/?utm_medium=email&utm_campaign=791%20Monday%20August%2019%20-%20Can%20controversial%20Sarepta%20scoop%20up%20another%20early%20OK%20for%20Duchenne%20MD%20This%20biotech%20raised%20100M%20for%20anti-aging%20RD&utm_content=791%20Monday%20August%2019%20-%20Can%20controversial%20Sarepta%20scoop%20up%20another%20early%20OK%20for%20Duchenne%20MD%20This%20biotech%20raised%20100M%20for%20anti-aging%20RD+CID_09c67b5e3f4fc4197c71932073266fc7&utm_source=ENDPOINTS%20emails&utm_term=EMA%20and%20FDA%20historically%20agree%20on%20just%20about%20every%20new%20drug%20approval%20but%20is%20that%20slowly%20changing
https://www.raps.org/news-and-articles/news-articles/2019/8/ema-and-fda-historically-agree-on-just-about-every
https://www.raps.org/news-and-articles/news-articles/2019/8/ema-and-fda-historically-agree-on-just-about-every
https://www.fiercepharma.com/pharma/goodbye-deerfield-takeda-sets-december-deadline-for-reassignment-1-000-u-s-employees
https://www.fiercepharma.com/pharma/takeda-swings-and-misses-ninlaro-al-amyloidosis-calls-off-phase-3-trial
https://endpts.com/takeda-suffers-another-setback-in-its-quest-to-expand-myeloma-drugs-reach-and-blockbuster-potential/
https://www.fiercepharma.com/marketing/asco-j-j-eyes-darzalex-convenience-safety-boost-subcutaneous-win
https://www.fiercepharma.com/pharma/takeda-cheers-strong-growth-from-key-drugs-despite-ninlaro-fda-snag
https://www.businesswire.com/news/home/20181101005805/en/Takeda-Present-Data-60th-American-Society-Hematology
https://www.ema.europa.eu/documents/product-information/ninlaro-epar-product-information_en.pdf
https://www.fiercepharma.com/pharma-asia/take-note-i-o-players-bristol-myers-to-sell-opdivo-china-at-half-its-u-s-price-report
https://www.biocentury.com/bc-extra/politics-policy/2018-08-17/china-unveils-cancer-drugs-medical-insurance-access-negotiation
https://www.fiercepharma.com/pharma/lack-late-stage-assets-at-takeda-don-t-worry-shire-has-it-covered
http://www.pmlive.com/pharma_news/immunology_keeps_shire_figures_solid_as_takeda_takeover_nears_1246459
http://www.pmlive.com/pharma_news/takeda_cant_sway_nice_on_oral_myeloma_therapy_ninlaro_1204447
https://www.statnews.com/2017/06/23/china-death-penalty-research-fraud/
http://www.in-pharmatechnologist.com/Drug-Delivery/Takeda-breaks-ground-on-45m-Ninlaro-plant-in-Ireland
http://www.fiercepharma.com/marketing/takeda-sporting-a-new-look-cancer-portfolio-gears-up-for-roche-battle-alk
http://www.fiercepharma.com/pharma/takeda-shells-out-whopping-5-2b-for-ariad-iclusig-and-its-fledgling-med-brigatinib
https://www.pharmacompass.com/pdf/news/takeda-gets-eu-nod-forninlaro-ixazomib-citrate-1481198182.pdf
http://www.pharmatimes.com/news/conditional_eu_nod_for_takedas_ninlaro_1179504
http://www.fiercepharma.com/pharma/j-j-s-darzalex-jumps-into-second-line-race-new-fda-approval?
http://www.fiercepharma.com/pharma-asia/takeda-ceo-says-new-myeloma-drug-ninlaro-will-be-significantly-bigger-than-velcade
http://www.fiercepharma.com/pharma/reorg-new-meds-help-takeda-crawl-out-profit-hole
http://www.reuters.com/article/us-health-cancer-costs-idUSKCN0XX21H
http://www.in-pharmatechnologist.com/Ingredients/Ash-Stevens-to-make-API-for-Takeda-s-new-oral-blood-cancer-drug
http://www.fiercebiotech.com/story/takedas-breakthrough-velcade-heir-wins-early-fda-approval-myeloma/2015-11-20
http://www.pharmatimes.com/Article/15-09-09/US_priority_review_for_Takeda_s_multiple_myeloma_drug.aspx
http://www.fiercebiotech.com/story/takeda-rolls-toward-eu-approval-its-heir-velcade/2015-08-21
http://www.pharmatimes.com/Article/15-07-14/Takeda_files_ixazomib_in_the_US_for_multiple_myeloma.aspx?utm_source=dlvr.it&utm_medium=twitter
Market Place
Share 
